A Phase 1 Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Aug 2018
At a glance
- Drugs BAY 1093884 (Primary)
- Indications Haemophilia
- Focus Pharmacokinetics
- Sponsors Bayer
- 31 Aug 2018 Biomarkers information updated
- 17 Aug 2018 Planned End Date changed from 17 Oct 2018 to 9 Nov 2018.
- 17 Aug 2018 Status changed from recruiting to active, no longer recruiting.